Thanks @Saus for your response. Appreciated.
Yes, Acadia doesn't have any rights to NNZ-2591 as yet.
Hence the reason for my post and questions.
If NNZ-2591 is safe and more effective than Trofinetide, then I makes little sense to try and run anymore costly and time consuming trials using Trofinetide.
Makes sense for Acadia to ask NEU to amend the current agreement to use NNZ-2591 or both for Fragile-z in the US ... at a cost of course.
This would also have a benefit for NEU as it would help NEU trial NNZ-2591 also, hopefully leading to a FDA approval for Fragile-X or Trofinetide.
GLTa
Thanks @Saus for your response. Appreciated.Yes, Acadia doesn't...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |